Expression and clinical significance of IL-17 and IL-17 receptor in ulcerative colitis

Abstract

The purpose of this study was to determine the expression levels of IL-17 in serum and IL-17 receptor (IL-17R) in intestinal mucosa tissue in patients with ulcerative colitis (UC) and con-trols, and evaluate their relationship with disease activity and explore the role of IL-17 in the patho-genesis of UC. A total of 36 Chinese UC patients and 60 healthy controls were enrolled in this study. Serum IL-17 and C-reactive protein (CRP) levels were determined by ELISA and immu-nonephelometry, respectively. The IL-17R mRNA expression levels were detected by quantitative PCR. Serum IL-17 levels were significantly elevated in UC patients as compared with those in the healthy controls (P<0.05). Among UC patients, serum IL-17 levels were significantly increased in active phase as compared with those in inactive phase (P<0.05), and correlated with CRP levels (r=0.578, P<0.01). IL-17R expression levels were higher in active UC patients than in healthy con-trols (P<0.05). It was concluded that IL-17 levels were highly expressed in UC, especially in active phase, and correlated with CRP levels in UC patients.

Keywords

ulcerative colitis / interleukin-17 / interleukin-17 receptor / serum / intestinal mucosa

References

[1] ShihDQ, TarganSR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol, 2008, 14(3): 390-400 PMCID: 2679127 PMID: 18200661

[2] KaserA, ZeissigS, BlumbergRS. Inflammatory bowel disease. Annu Rev Immunol, 2010, 28: 573-621 PMCID: 4620040 PMID: 20192811

[3] StroberW, FussI, MannonP. The fundamental basis of inflammatory bowel disease. J Clin Invest, 2007, 117(3): 514-521 PMCID: 1804356 PMID: 17332878

[4] KobayashiT, OkamotoS, HisamatsuT, et al. . IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut, 2008, 57(12): 1682-1689 PMID: 18653729

[5] RovedattiL, KudoT, BiancheriP, et al. . Differential regulation of interleukin-17 and interferon-γ production in inflammatory bowel disease. Gut, 2009, 58(12): 1629-1636 PMID: 19740775

[6] SatsangiJ, SilverbergMS, VermeireS, et al. . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implication. Gut, 2006, 55(12): 749-753 PMCID: 1856208 PMID: 16698746

[7] OikonomouKA, KapsoritakisAN, KapsoritakiAI, et al. . Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm Bowel Dis, 2011, 17(4): 963-970 PMID: 20629092

[8] AndohA, YagiY, ShioyaM, et al. . Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol, 2008, 14(33): 5154-5161 PMCID: 2744005 PMID: 18777592

[9] FussIJ, NeurathM, BoirivantM, et al. . Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol, 1996, 157(3): 1261-1270 PMID: 8757634

[10] FussIJ, HellerF, BoirivantM, et al. . Nonclassical CD1d restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest, 2004, 113(10): 1490-1497 PMCID: 406524 PMID: 15146247

[11] ElsonCO, CongY, WeaverCT, et al. . Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology, 2007, 132(7): 359-2370

[12] KornT, BettelliE, OukkaM, et al. . IL-17 and Th17 cells. Annu Rev Immunol, 2009, 27: 485-517 PMID: 19132915

[13] RaoDA, EidRE, QinL, et al. . Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. J Exp Med, 2008, 205(13): 3145-3158 PMCID: 2605225 PMID: 19075290

[14] KomiyamaY, NakaeS, MatsukiT, et al. . IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol, 2006, 177(1): 566-573 PMID: 16785554

[15] ZhangZ, ZhengM, BindasJ, et al. . Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis, 2006, 12(5): 382-388 PMID: 16670527

[16] HovhannisyanZ, TreatmanJ, LittmanDR. Characterization of IL-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology, 2011, 140(3): 957-965 PMCID: 3049831 PMID: 21147109

[17] YangXO, ChangSH, ParkH, et al. . Regulation of inflammatory responses by IL-17F. J Exp Med, 2008, 205(5): 1063-1075 PMCID: 2373839 PMID: 18411338

[18] FujinoS, AndohA, BambaS, et al. . Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 2003, 52(1): 65-70 PMCID: 1773503 PMID: 12477762

[19] KinugasaT, SakaguchiT, GuX, et al. . Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology, 2000, 118(6): 1001-1011 PMID: 10833473

[20] O’ConnorWJr, KamanakaM, BoothCJ, et al. . A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol, 2009, 10(6): 603-609 PMCID: 2709990 PMID: 19448631

[21] Mieliauskaite D, Dumalakiene I, Rugiene R, et al. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndrome. Clin Dev Immunol, 2012,2012:187258

[22] VincentFB, NorthcottM, HoiA, et al. . Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Therapy, 2013, 15(4): R97